Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs. This highlights the presence of residual cardiovascular risk in a significant proportion of patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangoni, Arduino A, Tommasi, Sara, Zinellu, Angelo, Sotgia, Salvatore, Carru, Ciriaco, Piga, Matteo, Erre, Gian Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239018/
https://www.ncbi.nlm.nih.gov/pubmed/30459819
http://dx.doi.org/10.7573/dic.212557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239018/
https://www.ncbi.nlm.nih.gov/pubmed/30459819
http://dx.doi.org/10.7573/dic.212557

Ejemplares similares